2011 INTERCEPT Conference Abstracts

26th General Meeting of the Belgian Hematological Society (BHS)
January 28 - 29, 2011 | Liege, Belgium

• Vandermeersch, I Vanlaere, R Matton et al.  The Effect of INTERCEPT Treatment on Concurrent Plasma Obtained from Platelet Apheresis Collection:  Functions and Factors.

• Elliott A, Lin L, Propst L et al in collaboration with the INTERCEPT Hemovigilance Study Centers. An Active Hemovigilance Program Provides Real-Time Data to Monitor the Safety of INTERCEPT Platelet and Plasma Components.
  [Poster PDF]
   
• Kientz D, Waller C, Isola H et al. The Frequency of Transfusion Related Sepsis Imputed to Platelet Components: Impact of Pathogen Inactivation.
  [Poster PDF]

12th International Conference on Thalassaemia and the Haemoglobinapathies
14th TIF International Conference for Patients and Parents
May 11 - 15, 2011 | Antalya, Turkey

• North AK, Erickson AE, Mufti NA et al.  Rabbit Models of Immune Response to Pathogen Inactivated (PI) Red Blood Cells (RBC). 
  [Poster PDF]
   
• Reed WF, Cancelas JA, Szczepiorkowski et al.  Clinical and Immunologic Evaluation of Red Blood Cell Components (RBCs) Prepared Using a Second Generation S-303 Pathogen Inactivation (PI) Process.
   

XXIst Regional Congress of the International Society of Blood Transfusion (ISBT)
June 18 - 23, 2011| Lisbon, Portugal

• Abedi MR, Doverud AC.  Validation of Double Dose Platelet Products for Pathogen Inactivation with the INTERCEPT Blood System and Storage for up to 7 Days.
  [Poster PDF]
   
• Baumann-Baretti, Jaster G, Brys B et al.  The Influence of Different Holding Conditions of Coagulation Parameters of Plasma After Pathogen Reduction with the INTERCEPT Treatment.
   
• Corash L, Sherman C, Reed W et al.  Hemostatic Efficacy of Platelet Components Treated with Amotosalen-UVA Pathogen Inactivation and Stored for 5 and 7 Days Prior to Transfusion.
  [Poster PDF]
   
• Dias F, Bini-Antunes M, Pereira M et al.  Photochemical Treatment of Fresh Plasma.  Evaluation of Functional Activity of Coagulation Factors and Inhibitors. 
  [Abstract PDF]
   
• Domanovic D, Cukjati M, Molojkovic A.  Two Years of Experience with the Transfusion of Pathogen Inactivated Platelets Using the INTERCEPT Blood System and 7 Day Storage. 
   
• Erickson A, Henschler R, Janetzko K et al.  In Vitro Evaluation of Pathogen Inactivated RBC Using the S-303 Treatment System.
  [Poster PDF] [Abstract PDF]
   
• Fernandez AC, Otero CA, Rodriguez Calvo MI.  Pathogen Reduction Treatment Using Amotosalen and Ultraviolet-A Light:  Process Control.
   
• Goslings D, Lodemann P, Yavuzcan G et al.  Validation and Implementation of the INTERCEPT Blood System for Platelets for Pathogen Inactivation of Apheresis and Buffy-Coat Products at One of the Biggest Regional Blood-Centers of Switzerland.
  [Abstract PDF]
   
• Goslings D, Valek A, Frey BM.  First Validation and Implementation of the Orbisac System in a Swiss Blood Center within the Scope of Introducing the Pathogen Inactivation System INTERCEPT.
  [Abstract PDF]
   
• Izquierdo MY, Fontecha EF, Moya San Pedro MA et al.  Analysis of Functional Activity of a Large Panel of Coagulation Factors in Fresh and Previously Frozen Plasma Treated with the INTERCEPT Blood System.
  [Abstract PDF]
   
• Lin L, Stassinopoulos A, Corash L.  Cumulative Clinical Data of INTERCEPT Blood System for Platelets Demonstrate Ability to Replace Gamma Irradiation in Routien Clinical Use for TA-GVHD Prevention. 
  [Poster PDF]

British Blood Transfusion Society Annual Conference (BBTS)
September 7 - 10, 2011 | Glasgow, Scotland

• Erickson A, Leibacher J, Erterek B et al.  In Vitro Evaluation of Pathogen Inactivated RBC Using the S-303 Treatment System.
  [Poster PDF]
   
• Stassinopoulos A, Corash L.  Replacement of Gamma Irradiation by Amotosalen Treatment Cumulative Clinical Data of Routine Use.
  [Poster PDF]

Deutsche Gesellschaft für Transfusionsmedizin (DGTI)
September 27 - 30 , 2011 | Hannover, Germany

• Corash L, Elliott A, Sherman C et al.  Platelets Clinical Studies Oral 42 Safety of Platelet Components Prepared with Amotosalen-UVA Pathogen Inactivation Treatment (INTERCEPT) Transfused In Routine Practice.   [Oral]
   
• Kientz D.  Critical Evaluation of Available Pathogen Inactivated Plasma Products in France.
  [Poster PDF]
   
• Kientz D, Remy E, Cinqualbre J et al.  Efficacy and Safety of Quarantine Plasma Compared To Pathogen Inactivated Plasma (INTERCEPT) for Support of Hepatic Transplantation. 
   
• Leibacher J, Erickson A, Giese M et al.  Plasma Implementation Poster 45 Pathogen Inactivation of Erythrocyte Concentrates Using the S-303 INTERCEPT System.
   
• Sherman C, Reed W, Corash L.  Hemostasis Endpoints(EP) in Platelet Transfusion Clinical Trials with Differential Follow-up.

American Association of Blood Banks Annual Meeting & TXPO (AABB)
October 22 - 25, 2011 | San Diego, CA

• Erickson A, Hanson D, Donnelly B et al.  Process Robustness of the S-303 Pathogen Inactivation System for Red Blood Cells.
  [Poster PDF]
   
• Hanson D, Arnold D, Sawyer L. Methicillin Resistance Does Not Impact the Sensitivity of Staphylococcus aureus to Inactivation by Amotosalen and UVA Illumination.
  [Poster PDF]
   
• Knutson F, Loef H, Pinkowski L et al.  Characteristics of Liquid Plasma treated with the INTERCEPT Blood System for Pathogen Inactivation and Stored at 4°C for 14 days.
  [Poster PDF]
   
• Osselaer JC, Vandendaele MC, Guldenpfennig M et al.  Influence on HLA Alloimmunisation Frequency in Hematology Patients Supported with INTERCEPT Pathogen Inactivated (PI) Platelet Components.
  [Poster PDF]
   
• Sherman C, Reed W, Corash L.  Hemostasis Endpoints in Platelet Transfusion Clinical Trials with Differential Follow-up.
  [Poster PDF]

HAA-ISHAPD Annual Scientific Meeting
October 30 - November 2, 2011 | Sydney, Australia

• Elliot A, Propst M, Corash L.  An Active Hemovigilance Program Provides Safety Data for Transfusing INTERCEPT Platelet and Plasma Components in Routine Clinical Practice.
  [Poster PDF]
   
• Erickson A, Leibacher J, Erterek B et al.  In Vitro Evaluation of Pathogen Inactivated RBC Using the S-303 Treatment System.
  [Poster PDF]
   
• Sawyer L, Wilson M, Holtan M.  Inactivation of Transfusion-Transmitted Vector-Borne Pathogens.
  [Poster PDF]
   
• Wilson M, Stassinopoulos A.  Hemovigilance Data of INTERCEPT Blood System for Platelets Demonstrate Reduced Adverse Transfusion Reactions and Ability to Protect Against TA-GVHD and Transfusion Related Sepsis.

XV congress Nazionale della Societa’ di Emaferesi e Manipolazione Cellulare (XV Congress of National Society for Haemapheresis and Cell Manipulation) (SidEM)
November 9 - 11, 2011 | Torino, Italy

• Infanti L, Sigle J, Buser A.  Clinical Experience with the Basel Principle: Double Dose Apheresis Platelet Components Treated with INTERCEPT Pathogen Inactivation.

XXIInd Regional Congress of the International Society of Blood Transfusion (ISBT)
November 20 - 23 , 2011 | Taipei, Taiwan

• Cinqualbre J, Kientz D, Remy E et al.  Platelets Inactivation Poster 57 Comparative Effectiveness of Plasma Prepared with Pathogen Inactivation
  (INTERCEPT) and Quarantine Conventional Plasma for Support of Liver Transplantation.  
   
• Erickson A, Donnelly B, Schott M et al.  In Vitro Evaluation of Pathogen Inactivated RBC Using the S-303 Treatment System.
  [Poster PDF]
   
• Erickson A, Leibacher J, Schott M et al.  Verification of In Vitro Quality of Pathogen Inactivated RBC Using the S-303 Treatment System.
  [Poster PDF]
   
• Hanson D, Arnold D, Sawyer L.  Inactivation of Clinically Relevant Numbers of Bacteria in RBC Using the S-303 Treatment System.
   
• Kwon SY, Bae JE, Lee JI et al.  Pathogen Inactivation Efficacy of Mirasol PRT System and INTERCEPT Blood System for Platelet-Rich Plasma Derived Platelets Suspended
  in Plasma.